Osteoclast-targeting nanomaterials are a family of drug-delivery designs that use bone-targeting molecules to concentrate a reactive payload at the osteoclast — the cell that resorbs bone. They appear in several patents collected in the source archive Bone Glue dossier, in two related variants: inhibition of osteoclasts via their acidic resorption zone, and prevention of tumor bone metastasis via tumor–osteoclast conjugates.
The acidic sealing zone variant
The osteoclast resorbs bone within a sealed, acidified compartment. Two patents in the dossier exploit this:
- US2022313609 — Nano composite material aiming at an acidic sealing zone in osteoclasts. Comprises a nanomaterial, bone-targeting molecules, and a compound able to react with the osteoclast acidic sealing zone. After bone-targeting modification, the nanomaterial is loaded with the reactive compound. The stated mechanism is "accurate mature osteoclast targeting and chemically regulated biocascade effects" that inhibit osteoclasts.
- CN111481678 — Nano material for osteoclast acidic closed region. Same architecture: nanomaterial plus bone-targeting molecules plus a compound that reacts in the osteoclast acidic closed region, inhibiting osteoclasts through "physiological chemical reaction regulated biological cascade reaction."
The tumor–osteoclast coupling variant
WO2025146088 — Nanomaterial for preventing tumor bone metastasis. Claims a "spatiotemporal coupling interaction between tumor cells and osteoclasts" and designs a physical-killing nanomaterial targeting tumor–osteoclast conjugates. The nanomaterial is a bone-targeting-group-modified nanovesicle encapsulating a carbonate compound and a phosphate compound. When tumor cells are activated, acid secretion by tumor-related osteoclasts in nearby conjugates triggers the carbonate compound to generate carbon dioxide gas and promotes release of the phosphate compound, which forms calcium phosphate crystals with calcium ions to kill nearby tumor cells. The stated aim is specific very-early tumor metastasis inhibition, avoiding drug resistance and biochemical drug resistance.
The circRNA variant
Two patents in the dossier target osteoclast precursor cells through a circular RNA rather than a nanomaterial payload:
- CN116024210 — Osteoporosis marker circRNA. Reports that circBBS9 and its human homologues are elevated in osteoporosis, and that miR-423-3p is a downstream target of circBBS9. Inhibiting circBBS9 is said not to affect differentiation of osteoclast mononuclear precursors but to weaken osteoclast polynucleation and bone resorption, and to increase bone density in osteoporosis mice.
- CN116019779 — Osteoporosis treatment delivery system based on osteoclast precursor cell targeting circBBS9 knock-down. Uses siRNA to inhibit circRNA in osteoclast precursor cells, weakening osteoclast polynucleation and bone resorption while preserving other precursor-cell functions. Delivery uses cell-membrane microvesicles homologous to osteoclast precursor cells.
Evidence status
These are patent abstracts. The dossier provides no grant status, prosecution outcome or experimental validation. The mouse bone-density result in CN116024210 is a claim within a patent document, not an independently reported finding. See Patent as Evidence.
Related
Source notes & attribution
- https://rexresearch.com/XianfengBoneGlue/XianfengBoneGlue.html